Integrated Management of Adolescent and Adult Illness (IMAI)
July 2008
Review Article
Granich et al. Int J Virol AIDS 2018, 5:043 DOI: 10.23937/2469-567X/1510043 Volume 5 | Issue 1
INT J TUBERC LUNG DIS 22(2):197–205 http://dx.doi.org/10.5588/ijtld.17.0245
HIV/AIDS - Research and Palliative Care 2016:8 183–193
The new Global Obstructive Lung Disease (GOLD) guidelines advice to focus treatment in Chronic Obstructive Pulmonary Disease (COPD) on improvement of functional state, prevention of disease progression and minimization of symptoms. So far no validated questionnaires are available to measure symptom ...and functional state in daily clinical practice. The aim of this study was to develop and validate the Clinical COPD Questionnaire (CCQ).
more
Journal of the International AIDS Society Vol. 21 (2018) e25133
Many prevention of mother-to-child HIV transmission programmes across Africa initiate HIV-infected (HIV positive) pregnant women on lifelong antiretroviral therapy (ART) on the first day of antenatal care (“same-day” initiation...). However, there are concerns that same-day initiation may limit patient preparation before starting ART and contribute to subsequent non-adherence, disengagement from care and raised viral load. We examined if same-day initiation was associated with viral suppression and engagement in care during pregnancy.
The data suggest that same-day ART initiation during pregnancy is not associated with lower levels of engagement in care or viral suppression through 12 months post-delivery in this setting, providing reassurance to ART programmes implementing Option B+.
https://doi.org/10.1002/jia2.25133
more
HIV-related advocacy evaluation training for civil society organisations
Open AccessPublished:March 28, 2019DOI:https://doi.org/10.1016/S1473-3099(18)30730-8
The Lancet Infectious Diseases
Supplement Article
J Acquir Immune Defic Syndr Volume 75, Supplement 2, June 1, 2017 www.jaids.com
DHS Working Papers No. 112 | Zimbabwe Working Papers No. 13
China and other so-called “emerging” donors and creditors are fundamentally changing the international development finance landscape; however, many of these actors do not participate in existing global reporting systems, such as the OECD’s Creditor Reporting System (CRS) and the International ...Aid Transparency Initiative (IATI).
To address this challenge and help those who seek to understand the nature, distribution, and effects of development finance from emerging donors and creditors, AidData developed the Tracking Underreported Financial Flows (TUFF) in collaboration with an international network of researchers from Harvard University, Heidelberg University, the University of Göttingen, the University of Cape Town, Brigham Young University, and William and Mary.
The methodology codifies a systematic, transparent, and replicable set of procedures that facilitate the collection of information about aid and credit from official sector donors and lenders who do not publish comprehensive or detailed information about their overseas activities. It does so by synthesizing and standardizing vast amounts of unstructured, open-source, project-level information published by governments, intergovernmental organizations, companies, nongovernmental organizations, journalists, and research institutions.
more
Heart failure (HF) is a leading global public health problem with >64 million prevalent cases globally. Patients with HF with reduced ejection fraction (HFrEF) from low- and middle-income countries experience a 22% to 58% higher 1-year mortality rate than those in high-income countries.1 Guideline-d...irected medical therapy (GDMT) consisting of ACE (angiotensin-converting enzyme) inhibitors or ARB (angiotensin receptor blockers) or ARNI (angiotensin receptor-neprilysin inhibitors), β-blockers, MRA (mineralocorticoid receptor antagonists), and SGLT2 (sodium-glucose cotransporter 2) inhibitors substantially reduces mortality among patients with HFrEF. These medicines are among the most cost-effective interventions and are thus included as the highest priority health system interventions recommended by the Disease Control Priorities Project.2 Despite this high-quality evidence, GDMT remains widely underutilized in low- and middle-income countries resulting in widespread undertreatment of patients with HFrEF due to health system-, provider-, and patient-level barriers.1 National essential medicines lists (EMLs) promoted by the World Health Organization (WHO) guide countries on which medications to purchase in the setting of limited resources and have resulted in higher procurement and availability of essential medicines in the public sector.3 We provide a cross-sectional analysis of national EMLs in 53 low- and middle-income countries, and availability, price, and affordability of GDMT in select countries to identify potential barriers to access to these essential medicines for patients with HFrEF.
more
COVID - 19 and PREGNANCY
Management guidelines for SARS-CoV-2 infection
Mid-term review of The National AIDS Programme 2011-15
October 2013
Front. Malar. 3:1336324. doi: 10.3389/fmala.2025.1336324